Ezelutamide, a second-generation androgen receptor (AR) inhibitor, has shown promise in extending survival for patients with castration-resistant prostate cancer (CRPC) and its potential in CRC treatment was explored by Shah et al. Here, AR is linked to colorectal carcinoma.